Acumen Pharmaceuticals Ownership
| ABOS Stock | USD 1.45 0.01 0.68% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Acumen |
Acumen Stock Ownership Analysis
About 77.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.4. Some equities with similar Price to Book (P/B) outperform the market in the long run. Acumen Pharmaceuticals recorded a loss per share of 1.38. The entity had not issued any dividends in recent years. Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimers disease. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. Acumen Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. For more info on Acumen Pharmaceuticals please contact Daniel MBA at 434 297 1000 or go to https://acumenpharm.com.Besides selling stocks to institutional investors, Acumen Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Acumen Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Acumen Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Acumen Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
About 11.0% of Acumen Pharmaceuticals are currently held by insiders. Unlike Acumen Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Acumen Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Acumen Pharmaceuticals' insider trades
Acumen Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Acumen Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acumen Pharmaceuticals backward and forwards among themselves. Acumen Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Acumen Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 864.5 K | T. Rowe Price Associates, Inc. | 2024-09-30 | 849.6 K | Hudson Bay Capital Management Lp | 2024-09-30 | 636 K | Pathstone Holdings Llc | 2024-09-30 | 517.3 K | State Street Corp | 2024-09-30 | 516.4 K | Jane Street Group Llc | 2024-09-30 | 487.6 K | Two Sigma Advisers, Llc | 2024-09-30 | 469.1 K | Two Sigma Investments Llc | 2024-09-30 | 309.5 K | Northern Trust Corp | 2024-09-30 | 308.9 K | Ra Capital Management, Llc | 2024-09-30 | 14.9 M | Franklin Resources Inc | 2024-09-30 | 3.5 M |
Acumen Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acumen Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acumen Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Acumen Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Acumen Pharmaceuticals Outstanding Bonds
Acumen Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Acumen Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Acumen bonds can be classified according to their maturity, which is the date when Acumen Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ACTIVISION BLIZZARD INC Corp BondUS00507VAQ23 | View | |
| US00507VAP40 Corp BondUS00507VAP40 | View | |
| ACTIVISION BLIZZARD INC Corp BondUS00507VAM19 | View | |
| ACTIVISION BLIZZARD INC Corp BondUS00507VAK52 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| ACTAVIS FDG SCS Corp BondUS00507UAS06 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.